China biopharma player gets $25m Series B
CANbridge Life Science, a Beijing-based clinical-stage biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has raised a Series B round worth $25 million.
Beijing-based life science specialist Lapam Capital led the financing round, joined by other investors including Qiming Venture Partners, Yuanming Capital, Yanyuan Capital, Biossom Investment Management...
More on Greater China
Latest News
ADIA commits $83m to India's Aditya Birla Health Insurance
Abu Dhabi Investment Authority (ADIA) has agreed to invest INR 6.6bn (USD 83.5m) in India’s Aditya Birla Health Insurance (ADBHI) for a 10% stake.
Bain targets $102m Japan advertising take-private
Bain Capital has won board approval from Net Marketing, a Tokyo-listed online advertising and media management business, for a take-private that values the company at approximately JPY 13.6bn (USD 102m).
China's Insilico Medicine gets another $35m
Insilico Medicine, a China-based artificial intelligence-driven drug discovery company, has closed the second tranche of its Series D round on USD 35m, with Prosperity7 Ventures taking the lead.
Singapore crypto risk platform extends Series A to $24m
Singapore’s Merkle Science, a predictive crypto analytics platform, has raised USD 24m in Series A funding led by K3 Ventures, Darrow Holdings, and Beco Capital.